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In Gaucher Disease (GD) the enzyme (imiglucerase) replacement therapy (ERT) is not able to stop the progression of the
neurological involvement, while the substrate reduction therapy (SRT), performed by N-Butyldeoxynojirimycin (miglustat), is
an alternative that should be evaluated. Two sisters, presenting the same genotype (R353G/R353G), were diagnosed as suﬀering
from GD; one of them later developed neurological alterations identiﬁed by quantitative saccadic eye movements analysis. The
aim of the study was to quantitatively measure the miglustat eﬀects in this GD neurological patient. Eye movement analysis during
subsequentcontrolswasperformedbyestimatingthecharacteristicparametersofsaccadicmainsequence.Thestudydemonstrates
that the SRT alone can be eﬀective in GD3. Moreover, it conﬁrms that quantitative eye movement analysis is able to precociously
identify also slight neurological alterations, permitting more accurate GD classiﬁcation.
1.Introduction
Gaucher disease (GD) is an autosomal recessive lysosomal
glycolipid storage disorder characterized by the accumula-
tion of glucocerebroside (glucosylceramide) in reticuloen-
dothelial cells [1].
Thegenecodingforthedeﬁcientenzymeglucocerebrosi-
dase (acid beta-glucosidase) is located on chromosome 1q21
[2]. Three phenotypes are traditionally recognized based
on the absence (type 1) or presence and severity (types 2
and 3) of CNS involvement. Speciﬁc mutations in the beta-
glucocerebrosidase gene are associated with speciﬁc clinical
presentations, for example, the L444P mutation produces
neurologic involvement.
The liver, the spleen, and long bones are the primary
organs aﬀected by the storage of glucosylceramide, mainly
derived from the normal turnover of leukocytes and erythro-
cytes. The highly cytotoxic substance glucosylsphingosine
(the nonacyl derivative of glucosylceramide) is also stored in
excess in the viscera and in the brain, leading to cell death.
Such neuronal destruction involves mainly the brain stem
and deep cerebellar nuclei, but the thalamus, basal ganglia,
and spinal cord are also aﬀected.
Type 3 (GD3) represents the subacute, juvenile neu-
ronopathic form, with onset in the teenage years and a
chronic course. The severity of GD3 is intermediate between
type 1 (GD1) and type 2 (GD2) with milder neurological
features. The ﬁrst symptoms are due to the massive visceral
involvement, and disorders of eye movements are the usual
presenting signs [3].
Adult patients [4, 5] in whom symptoms had begun
in late childhood, adolescence, or early adult years present
myoclonic epilepsy [6] and a distinctive supranuclear eye
movement disorder aﬀecting primarily horizontal gaze and
only occasionally vertical gaze [7–9]. The early defect in
horizontalgazeinvolvesthesaccadicsystem,andthedisorder
mimics closely congenital ocular motor apraxia [10]. Ocular
motor abnormalities include horizontal saccadic initiation
failure (SIF), with blinking, strabismus, slow horizontal and
downwardsaccades,andanabnormalvestibulo-ocularreﬂex
[10]. Horizontal SIF is the most consistent ﬁnding and is
frequently the ﬁrst sign of neurological involvement [11].2 Neurology Research International
Vertical SIF usually indicates a progression of the disease,
even if one case with vertical without horizontal SIF has
been pointed out [11]. Both quick phases of optokinetic
nystagmus [12] and voluntary saccades [13]c a nb eu s e dt o
early detect and follow the neurological involvement.
The phenotypic continuity between nonneuronopathic
and severe acute neuronopathic forms of Gaucher disease
(GD) is emerging from the literature [14–16], contrary to
a clear-cut distinction among the classical GD1, GD2, and
GD3 types. In a large series of French patients, the clinical
characteristics suggest that the three forms of GD each
involves a diﬀerent proﬁle of neurological manifestations
[17].
GD1 is treatable with appropriate amounts of exogenous
enzyme (imiglucerase) replacement therapy (ERT), whose
safety and eﬃcacy have been clearly documented [18].
Splenectomy is rarely necessary, since speciﬁc treatments
have recently become available. ERT is however unable to
stop the progression of the neurological involvement. Due to
the fact that infusion of glucocerebrosidase increases enzyme
activity in the CNS if a dosage of 120U/kg body weight
or higher is given [19], the role of such high-dose ERT in
neuronopathic cases was studied: it was concluded that the
latter is not able to stabilize neurological disease [20].
To protect the brain of GD patients, substrate reduc-
tion therapy (SRT) performed by N-Butyldeoxynojirimycin
(miglustat) could be an alternative. The formation of
glycosphingolipids is decreased to amounts that may be
metabolised by the residual enzyme [21]. In patients with
visceral GD, the eﬃcacy of SRT with miglustat has been
demonstrated [22], while the beneﬁt of miglustat also for
patients with neuronopathic GD is not proved, given the
contrasting results obtained [23, 24].
In this paper, the clinical history of two GD sisters, ini-
tially treated with ERT, is described. One of them developed
saccadiceyemovementalterationsthatdisappearedaftertwo
years of miglustat therapy.
2.CaseReport
Two sisters (F. I. and A. I.), out of 7 siblings (5 females,
2m a l e s ) ,o ﬀspring to second cousin parents, presenting
the same genotype (R353G/R353G), were GD diagnosed in
1983 and both submitted to splenectomy in the same year.
During adolescence, they presented epilepsy responsive to
barbiturate: generalized tonic-clonic seizures (patient F. I.)
and partial complex seizures (patient A. I.). A ﬁrst saccadic
eye movements recording was carried out in both patients
in year 2000, during their annual clinical control. The eye
movement recording was repeated in 2005 and in 2007.
F. I., born in 1961 and suﬀering from hepatosple-
nomegaly, anemia, thrombocytopenia, and bilateral necrosis
of the femoral epiphysis at the moment of diagnosis, began
ERT in 1995 (alglucerase/imiglucerase: 30U/kg every 2
weeks). At that time she showed liver cirrhosis without
signs of liver insuﬃciency; focal spike activity at EEG (left
temporal region); normal visual evoked potentials (VEP)
and auditory brain responses (ABR); increased threshold
intensity and reduced amplitude at upper limb motor-
evoked potentials. The 2005 control brought out that in the
previous 5 years ERT therapy had been performed without
continuity; therefore, treatment was changed to SRT miglu-
stat (200mg, 3 t.i.d) oral therapy. The barbiturate therapy
continued.Atthe2007control,livervolumeremainedstable,
no bone fracture was reported or detected, and the EEG
proved unchanged (infrequent focal paroxysmal discharges).
Themiglustattreatmentwasconﬁrmedowing tothe absence
of adverse events (gastrointestinal disturbances) in the two
y e a r so fo r a lt r e a t m e n t .
A. I., born in 1967 and suﬀering from splenomegaly,
anemia and thrombocytopenia at the moment of diagnosis,
began ERT in 2002 (regularly performed) because of a
hepatic involvement (imiglucerase: 15U/kg every 2 weeks).
At that time she did not manifest neurological signs and had
normal EEG and ABR, so that the barbiturate therapy was
stopped. The 2005 control evidenced diﬀu s eb o n ep a i n .S h e
changedthetreatmenttoSRTmiglustat(100mg,3t.i.d.)too,
oral therapy, that was conﬁrmed at the 2007 control, thanks
to the tolerability of the oral treatment.
Saccadic movements of both eyes were recorded by
means of the infrared limbus tracking technique (a very
accurate technique in cooperative patients), with the subject
looking at a target (a red light spot) in random horizontal
motion, in a visual range of ±15deg with amplitudes of 5,
10, 15, and 20deg. Two 70-movements tests were performed,
at a 30-minute interval. In both patients, the ophthalmic and
orthoptic examinations, performed before each saccadic test,
showed the absence of relevant ocular and/or oculomotor
disturbances.
For each identiﬁed saccade, the amplitude (A), duration
(D), latency, and peak velocity (Vp)w e r ec a l c u l a t e d .A/D
and A/Vp relationships (main sequence) were evaluated
and best ﬁtted. For the A/D relation a linear regression
(D = m
∗A+q) was used, while for the A/Vp relation
the ﬁtting curve was derived from the function Vp =
1/(α + β/A). The K (mean velocity/peak velocity ratio) and
Skewness (saccadic rise time/duration ratio) parameters,
able to provide a description of velocity responses, were
also evaluated [25, 26], and their relationships with the
Amplitude (A/K, A/Skewness) were examined by linear best
ﬁtting (K = mk ∗A+qk;S k e w n e s s= ms ∗A+qs)[ 26].
At a ﬁrst examination of the acquired traces, a worsening
was evident in the second test performed by F. I., with some
SIF tracts and frequent blinks; a recovery was instead evident
in the last recording.
The saccadic parameters, resulting from all the six
registrations, are summarized in Table 1, where the normal
values (obtained from a sample of 10 normal adult subjects
performing the same test) are also indicated.
While A. I. presents normal values in the three tests,
F. I. shows a signiﬁcant alteration of the main sequence at
the second test, characterized by saccadic slowing (lower 1/α
values in the A/Vp relationship, P<. 05) with duration
increase (greater m slope in the A/D relationship, P<
.01) and a subsequent improvement after miglustat therapy.
Moreover, from 2000 to 2007 she presents a large reduction
in mk slope and an increase in ms slope in the A/KNeurology Research International 3
Table 1: Eye movement characteristic parameters in the two GD sisters (A. I. and F. I.) compared to mean values and SD of 10 normal
subjects (and corresponding conﬁdence interval at P = .05). A/D m: slope of the amplitude/duration linear relationship; A/D q: intercept
of the amplitude/duration linear relationship; A/Vp 1/α: velocity saturation value of the non linear amplitude/peak velocity relationship;
A/Vp 1/β: slope at the lowest amplitude of the non linear amplitude/peak velocity relationship; A/K mk: slope of the linear amplitude/K
ratio relationship; A/SK ms: slope of the linear amplitude/skewness relationship.
A/D m A/D q A/Vp 1/α A/Vp 1/β Latency A/K mk A/SK ms
ms/deg ms deg/s 1/s ms 1/deg 1/deg
A. I.
2000 2.77 29 646 75 174 0.0041 −0.028
2005 2.61 31 628 63 198 0.0040 −0.026
2007 2.48 33 881 69 173 0.0015 −0.005
F. I.
2000 2.69 46 570 56 191 0.0031 −0.019
2005 8.77 50 259 56 203 −0.0002 −0.0006
2007 2.52 30 851 53 199 −0.0007 0.0014
Normal Subjects mean 1.86 36 1282 61 188 0.0023 −0.013
SD 0.47 5 355 15 36 0.0022 0.011
Conf. Int. (P = .05) min 0.86 25 524 28 111 −0.003 −0.036
max 2.86 47 2040 93 265 0.0072 0.01
and A/Skewness relationships, respectively, even though
their values appear within the normal conﬁdence interval
(Table 1).
3. Discussion
The two patients were initially treated with an ERT dosage
for GD1, because epilepsy was considered a casual event
not correlated to the CNS glycolipid storage observed in
GD3, and the barbiturate therapy was eﬀective. In fact,
even if it is known that barbiturate treatment could aﬀect
eye movements, in F. I. the therapy was always the same;
therefore, it is unlikely that the eye movement changes could
be due to barbiturate. In F. I., with more important visceral
symptoms, ERT was started more precociously, but during
the 2000−2005 period it was performed with considerable
discontinuity because of the unaccepted administration
route.Atthesecondeyemovementrecordingcontrol(2005),
some oculomotor signs of neurological involvement became
manifest,especiallythepeakvelocityreduction.Thepresence
of oculomotor abnormalities is a suﬃcient condition to
change the classiﬁcation from nonneuronopathic to neu-
ronophatic illness type, as indicated by Harris et al. [10]
andAccardoetal.[26].HerR353G/R353Ggenotype,already
p r o p o s e da san e u r o l o g i c a lt y p e[ 27] because of the presence
of epilepsy, is conﬁrmed as neurological owing to the onset
ofthenewoculomotoralterations.Weunderlinethatinspite
of the GD1 ERT dosage therapy, till about 40 years of age no
evidenceofneurologicalinvolvement(ifweexcludeepilepsy)
was present; this indicates a low grade of neurological
aggressiveness of this genotype. After two years of miglustat
therapy, the oculomotor signs disappeared, showing the
eﬃcacy of SRT to improve (even by itself and not only if
combined with ERT [23, 24]) some neurological symptoms.
A positive result in one GD3 patient with myoclonic epilepsy
was reported by Capablo et al. [23] using a combined
ERT and SRT therapy. In our case SRT therapy alone did
not inﬂuence the course of epilepsy, while it normalized
saccades. On the contrary, a controlled trial in 30 GD3
patients [24], where miglustat was used in addition to ERT,
did not show signiﬁcant diﬀerences in the neurological
signs (included saccadic eye movement characteristics) in
a 24-month period, while a positive eﬀect on systemic
disease (pulmonary function and chitotriosidase activity)
was observed. The vertical and horizontal saccadic velocities
were signiﬁcantly diﬀerent between the GD patients and
10 age-matched control subjects at the starting point, but
the standard deviation in the GD group was very large,
therefore including cases with low velocities and other cases
with normal ones. No signiﬁcant variation was observed
(in average) after miglustat therapy. Our case presented a
clear peak velocity reduction, only 259deg/s, which became
851deg/s after two years of therapy (SRT alone), a very
large variation (conﬁrmed by two tests). To compare our
results to other clinical cases, it would be interesting to know
whether GD patients with the lowest saccadic velocities in
the Schiﬀmann et al. series [24] clearly improved their ocular
motor ability after miglustat therapy (together to ERT).
In A. I., the clinical picture appears unchanged in the
2005 and 2007 controls: the eye movements were normal
as in 2000. In spite of the low dosage therapy and of the
neurological genotype R353G/R353G [27], at an age of 38
years she did not yet show other neurological signs (in
addition to the temporary epilepsy). Perhaps, the change of
therapy (from ERT to SRT) did not permit any further mild
neurological manifestation.
Concerning the presence of epilepsy, it was initially
considered as a casual event in the two patients. After
the appearance, in F. I., of new ocular motor pathological
signs, it seemed more probable that epilepsy was part of
the neurological picture of some GD3 patients. However,
the ineﬃcacy of the SRT therapy on EEG paroxysmal, with
the necessity to maintain the barbiturate therapy, seems
to indicate a low grade of brain activity of SRT, probably
able to recover from only light and initial neurological
manifestations.4 Neurology Research International
Considering the clinical course in the two siblings, it
can be hypothesised that the R353G homozygote genotype
corresponds to a low-aggressiveness and late-onset GD3
illness.
In F. I., eye movement analysis permitted to point out
the new slight neurological worsening, showing once more
thevalueofthisinstrumentalexaminationinmonitoring the
neurological situation, including the eﬃcacy of therapy. In
GD patients, beside eye movement examination, it is suitable
to execute other exams able to investigate the brain-stem
reticularformation,particularlythoseregardingtheauditory
pathways [28]. In fact, ocular motility is not the only
neurological aspect showing up at the beginning of GD3,
even if it is the most precocious [29]. Thus we recommend
the convenience to exam periodically ocular motility in
GD patients with risks genotypes to develop neurological
symptoms.
It was previously reported that some GD1 patients
present some slight eye movement alterations, related to
saccadic velocity proﬁles [30], or evident neurological symp-
toms [17], bringing forward the concept of a phenotypic
continuum from GD1 to GD3 classiﬁcation. This concept is
similar to the one that was already proposed by Goker et al.
[31] for the heavy neurological involvements: a continuum
between GD2 and GD3 classiﬁcation. The results of the
present study seem to be in agreement with this new
approach to the evaluation of GD patients.
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